Amgen Acquires Horizon Therapeutics for USD 27.8bn.

MANews-(C)2009-2023

US-based biotechnology company Amgen (NASDAQ: AMGN) has acquired Ireland-based biotechnology company Horizon Therapeutics plc for USD 116.50 per share in cash, representing a transaction equity value of approximately USD 27.8 bn, the company said.

The rationale for the acquisition includes:

Alignment with Amgen's core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases.

Strengthening of Amgen's leading inflammation portfolio by adding first-in-class, early-in-lifecycle medicines such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon), which treat rare inflammatory diseases.

Leveraging of Amgen's world-class capabilities in biologics research and development, process development and manufacturing, as well as Amgen's presence in more than 100 countries around the world.

Generating robust cash flow to support capital allocation priorities, including ongoing investment in innovation while...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT